American College of Medical Toxicology 2023 ACMT Seminar in Forensic Toxicology: Expanding Worlds of Cannabinoids & Polydrug Exposures Date of CE Release: 12-14-2023 Date of CE Expiration: 12-15-2024 Location: Online

Acknowledgement of Financial Commercial Support

No financial commercial support was received for this educational activity. **Acknowledgement of In-Kind Commercial Support** No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and American College of Medical Toxicology. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Amedco Joint Accreditation Provider Number: 4008163

Physicians

ACCME Credit Designation Statement

Amedco LLC designates this material for a maximum of 12.00 *AMA PRA Category 1 Credits*[™] for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Objectives - After Attending This Program You Should Be Able To

- 1. Recognize the historical and legislative drivers of cannabis legalization and cannabinoids.
- 2. Evaluate laboratory testing challenges and pharmacological mechanisms of cannabinoids.
- 3. Describe the complexities and challenges of forensic and medical toxicology in cases involving polydrugs.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

All individuals in a position to control the content of CE are listed in the program book. If their name is not listed below, they disclosed that they had no financial relationships with a commercial interest.

| Name | Commercial Interest:Relationship |
|---------------------|---|
| Deena Ryerson | NA |
| Ayako Chan-Hosokawa | NA |
| Joseph D'Orazio | NA |
| Natalie Desrosiers | NA |
| Adrienne Dunavin | NA |
| Jennie Duval | NA |
| Brent Furbee | Eli Lilly, Moderna, Pfizer, Astrazeneca, Amgen, Bristol Myers Squibb, Merck & Co, |
| | Unitedhealth Group Inc, Stryker Corp:Public Stock Shareholder |
| James Gill | NA |
| Bruce Goldberger | NA |
| Lucinda Gonzales | NA |
| Curt Harper | NA |
| Robert Hendrickson | NA |
| Andrew Holt | Aegis Sciences Corporation: Employee |
| Glen Jackson | NA |
| Bryan Judge | NA |
| Sherri Kacinko | NMS Labs:Employee |
| Erin Karschner | NA |
| Alex Krotulski | NA |
| Marc LeBeau | NA |
| Barry Logan | NA |
| Karen McDonald | NA |
| Charles McKay | NA |
| MJ Menendez | NA |
| Lewis Nelson | NA |
| Donna Papsun | NA |
| Jan Ramaekers | NA |
| Paul Wax | NA |
| Rachel Wightman | NA |
| Ryan Dixon | NA |
| | |

How to Get Your Certificate

- 1. Go to acmt.cmecertificateonline.com
- 2. Click on the **2023 ACMT Seminar in Forensic Toxicology: Expanding Worlds of Cannabinoids & Polydrug Exposures** link.
- 3. Evaluate the meeting.
- 4. Print, download, or save your certificate for your records.
- 5. If you lose your certificate, or need help, go to help.cmecertificateonline.com